Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray's Cesium-131
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Cesium Blu News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cesium Blu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cesium Blu Today - Breaking & Trending Today
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray's Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
Message : Required fields HOUSTON, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the prostate utilizing a single post-implant MRI procedure. This allows the ...
Source: marketscreener.com
Pre-market Movers In Healthcare Sector: ISR, GHSI, NMTR, Check-Cap, BBI.
Pre-market Movers In Healthcare Sector: ISR, GHSI, NMTR, Check-Cap, BBI. In the Green 1. Isoray Inc. (ISR) is up over 177% at $1.47 in pre-market hours Wednesday, following FDA 510(k) clearance for the use of C4 Imaging's Sirius positive-signal MRI Markers with the company's Cesium-131, brachytherapy seeds. Brachytherapy, or internal radiation therapy, is a cost-effective option for the treatment of prostate cancer. Isoray is the world's only producer of Cesium-131, commercially known as Cesium Blu, brachytherapy seeds. 2. Guardion Health Sciences Inc. (GHSI) is up over 47% at $0.81 in pre-m...
Source: finanznachrichten.de